Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy

Hao-Ying Li, Helen Neill, Rebecca Innocent, Peter Seville, Ian Williamson, James C. Birchall*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Spray-drying represents a viable alternative to freeze-drying for preparing dry powder dispersions for delivering macromolecules to the lung. The dispersibility of spray-dried powders is limited however, and needs to be enhanced to improve lung deposition and subsequent biological activity. In this study, we investigate the utility of leucine as a dry powder dispersibility enhancer when added prior to spray-drying a model non-viral gene therapy formulation (lipid:polycation:pDNA, LPD). Freeze-dried lactose-LPD, spray-dried lactose-LPD and spray-dried leucine-lactose-LPD powders were prepared. Scanning electron microscopy showed that leucine, increased the surface roughness of spray-dried lactose particles. Particle size analysis revealed that leucine-containing spray-dried powders were unimodally dispersed with a mean particle diameter of 3.12 μm. Both gel electrophoresis and in vitro cell (A549) transfection showed that leucine may compromise the integrity and biological functionality of the gene therapy vector. The deposition of the leucine containing powder was however significantly enhanced as evidenced by an increase in gene expression mediated by dry powder collected at lower stages of a multistage liquid impinger (MSLI). Further studies are required to determine the potential of leucine as a ubiquitous dispersibility enhancer for a variety of pulmonary formulations. © 2003 Taylor & Francis Ltd.

Original languageEnglish
Pages (from-to)425-432
Number of pages8
JournalJournal of Drug Targeting
Volume11
Issue number7
DOIs
Publication statusPublished - Aug 2003

Fingerprint

Leucine
Genetic Therapy
Powders
Lung
Lactose
Lipids
Freeze Drying
Particle Size
Electron Scanning Microscopy
Transfection
Electrophoresis
Gels
Gene Expression
polycations

Keywords

  • leucin
  • LPD complex
  • non-viral gene therapy
  • pulmonary deposition
  • spray-drying

Cite this

Li, H-Y., Neill, H., Innocent, R., Seville, P., Williamson, I., & Birchall, J. C. (2003). Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy. Journal of Drug Targeting, 11(7), 425-432. https://doi.org/10.1080/10611860410001659786
Li, Hao-Ying ; Neill, Helen ; Innocent, Rebecca ; Seville, Peter ; Williamson, Ian ; Birchall, James C. / Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy. In: Journal of Drug Targeting. 2003 ; Vol. 11, No. 7. pp. 425-432.
@article{478fa03ca1f244feab29215e11316d70,
title = "Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy",
abstract = "Spray-drying represents a viable alternative to freeze-drying for preparing dry powder dispersions for delivering macromolecules to the lung. The dispersibility of spray-dried powders is limited however, and needs to be enhanced to improve lung deposition and subsequent biological activity. In this study, we investigate the utility of leucine as a dry powder dispersibility enhancer when added prior to spray-drying a model non-viral gene therapy formulation (lipid:polycation:pDNA, LPD). Freeze-dried lactose-LPD, spray-dried lactose-LPD and spray-dried leucine-lactose-LPD powders were prepared. Scanning electron microscopy showed that leucine, increased the surface roughness of spray-dried lactose particles. Particle size analysis revealed that leucine-containing spray-dried powders were unimodally dispersed with a mean particle diameter of 3.12 μm. Both gel electrophoresis and in vitro cell (A549) transfection showed that leucine may compromise the integrity and biological functionality of the gene therapy vector. The deposition of the leucine containing powder was however significantly enhanced as evidenced by an increase in gene expression mediated by dry powder collected at lower stages of a multistage liquid impinger (MSLI). Further studies are required to determine the potential of leucine as a ubiquitous dispersibility enhancer for a variety of pulmonary formulations. {\circledC} 2003 Taylor & Francis Ltd.",
keywords = "leucin, LPD complex, non-viral gene therapy, pulmonary deposition, spray-drying",
author = "Hao-Ying Li and Helen Neill and Rebecca Innocent and Peter Seville and Ian Williamson and Birchall, {James C.}",
year = "2003",
month = "8",
doi = "10.1080/10611860410001659786",
language = "English",
volume = "11",
pages = "425--432",
journal = "Journal of Drug Targeting",
issn = "1061-186X",
publisher = "Informa Healthcare",
number = "7",

}

Li, H-Y, Neill, H, Innocent, R, Seville, P, Williamson, I & Birchall, JC 2003, 'Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy', Journal of Drug Targeting, vol. 11, no. 7, pp. 425-432. https://doi.org/10.1080/10611860410001659786

Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy. / Li, Hao-Ying; Neill, Helen; Innocent, Rebecca; Seville, Peter; Williamson, Ian; Birchall, James C.

In: Journal of Drug Targeting, Vol. 11, No. 7, 08.2003, p. 425-432.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Enhanced dispersibility and deposition of spray-dried powders for pulmonary gene therapy

AU - Li, Hao-Ying

AU - Neill, Helen

AU - Innocent, Rebecca

AU - Seville, Peter

AU - Williamson, Ian

AU - Birchall, James C.

PY - 2003/8

Y1 - 2003/8

N2 - Spray-drying represents a viable alternative to freeze-drying for preparing dry powder dispersions for delivering macromolecules to the lung. The dispersibility of spray-dried powders is limited however, and needs to be enhanced to improve lung deposition and subsequent biological activity. In this study, we investigate the utility of leucine as a dry powder dispersibility enhancer when added prior to spray-drying a model non-viral gene therapy formulation (lipid:polycation:pDNA, LPD). Freeze-dried lactose-LPD, spray-dried lactose-LPD and spray-dried leucine-lactose-LPD powders were prepared. Scanning electron microscopy showed that leucine, increased the surface roughness of spray-dried lactose particles. Particle size analysis revealed that leucine-containing spray-dried powders were unimodally dispersed with a mean particle diameter of 3.12 μm. Both gel electrophoresis and in vitro cell (A549) transfection showed that leucine may compromise the integrity and biological functionality of the gene therapy vector. The deposition of the leucine containing powder was however significantly enhanced as evidenced by an increase in gene expression mediated by dry powder collected at lower stages of a multistage liquid impinger (MSLI). Further studies are required to determine the potential of leucine as a ubiquitous dispersibility enhancer for a variety of pulmonary formulations. © 2003 Taylor & Francis Ltd.

AB - Spray-drying represents a viable alternative to freeze-drying for preparing dry powder dispersions for delivering macromolecules to the lung. The dispersibility of spray-dried powders is limited however, and needs to be enhanced to improve lung deposition and subsequent biological activity. In this study, we investigate the utility of leucine as a dry powder dispersibility enhancer when added prior to spray-drying a model non-viral gene therapy formulation (lipid:polycation:pDNA, LPD). Freeze-dried lactose-LPD, spray-dried lactose-LPD and spray-dried leucine-lactose-LPD powders were prepared. Scanning electron microscopy showed that leucine, increased the surface roughness of spray-dried lactose particles. Particle size analysis revealed that leucine-containing spray-dried powders were unimodally dispersed with a mean particle diameter of 3.12 μm. Both gel electrophoresis and in vitro cell (A549) transfection showed that leucine may compromise the integrity and biological functionality of the gene therapy vector. The deposition of the leucine containing powder was however significantly enhanced as evidenced by an increase in gene expression mediated by dry powder collected at lower stages of a multistage liquid impinger (MSLI). Further studies are required to determine the potential of leucine as a ubiquitous dispersibility enhancer for a variety of pulmonary formulations. © 2003 Taylor & Francis Ltd.

KW - leucin

KW - LPD complex

KW - non-viral gene therapy

KW - pulmonary deposition

KW - spray-drying

UR - http://www.scopus.com/inward/record.url?scp=1842483585&partnerID=8YFLogxK

UR - https://www.tandfonline.com/doi/abs/10.1080/10611860410001659786

U2 - 10.1080/10611860410001659786

DO - 10.1080/10611860410001659786

M3 - Article

C2 - 15203931

VL - 11

SP - 425

EP - 432

JO - Journal of Drug Targeting

JF - Journal of Drug Targeting

SN - 1061-186X

IS - 7

ER -